Inflammatory Myofibroblastic Tumor of the Uterus
- 1 October 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 29 (10), 1348-1355
- https://doi.org/10.1097/01.pas.0000172189.02424.91
Abstract
Inflammatory myofibroblastic tumor (IMT) is an indolent spindle cell proliferation that can histologically resemble various malignant mesenchymal neoplasms; however, it generally behaves as a benign or locally recurrent tumor. Most IMTs involve the lung, mesentery, omentum, or retroperitoneum. We report the clinical and pathologic features of six IMTs of the uterus, one of which was included in a previous report, and emphasize the histologic and immunohistochemical features that distinguish IMTs from uterine spindle cell neoplasms that require aggressive treatment. Recently, translocations of the anaplastic lymphoma kinase (ALK) gene and immunohistochemical expression of ALK have been reported in IMTs of various anatomic sites. We compared ALK expression in uterine IMTs with that in uterine mesenchymal neoplasms with which it may be confused. Patients with IMT were between 6 and 46 years of age. None had a history of abdominal surgery; three were multiparous. The IMTs ranged from 1 to 12 cm in maximum dimension. Three grew as polypoid masses that arose in the lower uterine segment, and two of these prolapsed through the cervical os. The three other tumors grew as bulky myometrial masses with focally irregular borders and infiltrated the endometrium, parametrium, or cervical stroma. There were three main microscopic patterns: a hypocellular pattern, a fascicular pattern, and a hyalinized pattern. A lymphoplasmacytic infiltrate was present in all of the tumors, and most had a myxoid background. Mitotic activity ranged from 0 to 2 mitotic figures per 10 high power fields (HPF) except in one tumor that focally had up to 8 mitotic figures per 10 HPF. No nuclear atypia or necrosis was present. Immunohistochemical expression of ALK was present in a cytoplasmic pattern in all IMTs tested. No ALK expression was identified in uterine leiomyoma (n = 7), leiomyosarcoma (n = 6), carcinosarcoma (n = 4), endometrial stromal sarcoma (n = 4), or normal uterine tissues. Follow-up ranging from 1.5 years to 5 years in 4 patients with uterine IMTs revealed no recurrence or metastasis. IMTs should be differentiated from aggressive uterine mesenchymal tumors because they can be treated conservatively and have a more favorable prognosis. ALK expression appears to be of diagnostic value in conjunction with other immunohistochemical stains.Keywords
This publication has 28 references indexed in Scilit:
- Surveillance, Epidemiology, and End Results analysis of 2677 cases of uterine sarcoma 1989–1999Gynecologic Oncology, 2004
- The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General HospitalGynecologic Oncology, 2004
- Inflammatory myoblastic tumor of the uterus and interleukin-6American Journal of Obstetrics and Gynecology, 2003
- Anaplastic Lymphoma Kinase (ALK) Expression in the Inflammatory Myofibroblastic TumorThe American Journal of Surgical Pathology, 2001
- ALK1 and p80 Expression and Chromosomal Rearrangements Involving 2p23 in Inflammatory Myofibroblastic TumorLaboratory Investigation, 2001
- Myofibroblastic Tumours: Neoplasias with Divergent Behaviour. Ultrastructural and Flow Cytometric AnalysisPathology - Research and Practice, 1999
- Progression of inflammatory myofibroblastic tumor (inflammatory pseudotumor) or soft tissue into sarcoma after several recurrencesHuman Pathology, 1996
- Inflammatory myofibroblastic tumor (Inflammatory pseudotumor): DNA flow cytometric analysis of nine pediatric casesCancer, 1996
- Extrapulmonary Inflammatory Myofibroblastic Tumor (Inflammatory Pseudotumor) A Clinicopathologic and Immunohistochemical Study of 84 CasesThe American Journal of Surgical Pathology, 1995
- Plasma cell granulomas of the lungCancer, 1973